[1]Nationwide survey of specialist knowledge on current standard of care (Peg-IFN/RBV) and barriers of care in chronic hepatitis C patients in China [2]Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C [3]Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a [4]Daclatasvir plus asunaprevir in treatment-naive patients with hepatitis C virus genotype 1b infection [5]Safety and efficacy of an all-oral interferon-free regimen of seraprevir, an NS3/4A protease inhibitor and sofosbuvir in patients with chronic hepatitis C virus (HCV) genotype 1: an open-label, multicentre, phase 3 trial [6]A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infection [7]Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial [8]Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection [9]A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin [10]SOFOSBUVIR-CONTAINING ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS C VIRUS INFECTION IN RENAL TRANSPLANT RECIPIENTS: A SINGLE-CENTER INITIAL EXPERIENCE